Thermo Fisher Scientific Q1 2025 Earnings Summary

Financial highlights
- Revenue: $10.36 billion, slightly up from $10.34 billion in Q1 2024
- GAAP diluted EPS: $3.98, an increase of 15 percent year-over-year
- Adjusted EPS: $5.15, a 1 percent increase from Q1 2024
- Free cash flow: $373 million, down from $908 million in the prior-year quarter

Margins and operating performance
- GAAP operating margin: 16.6 percent, compared to 16.1 percent a year ago
- Adjusted operating margin: 21.9 percent, compared to 22.0 percent in Q1 2024
- GAAP operating income: $1.72 billion
- Adjusted operating income: $2.27 billion

Segment revenue (Q1 2025)
- Life sciences solutions: $2.34 billion
- Analytical instruments: $1.72 billion
- Specialty diagnostics: $1.15 billion
- Laboratory products and biopharma services: $5.64 billion

Strategic and operational developments
- New product launches included Vulcan automated lab for semiconductor analysis, Olink Reveal proteomics kits for inflammation research, and Cryofuge, BIOS, and LYNX centrifuges featuring energy-efficient refrigeration
- Strategic partnership with the Chan Zuckerberg Institute for biological imaging technology
- Launch of CorEvitas registries for systemic lupus erythematosus and adolescent alopecia areata

Acquisitions and capital deployment
- Agreement to acquire Solventum’s purification and filtration business for $4.1 billion
- Repurchased $2.0 billion of stock
- Increased quarterly dividend by 10 percent

Outlook
- Updated 2025 financial guidance to be provided during the April 23 earnings call

CEO commentary
Marc N. Casper emphasized strong operational execution in a challenging macroeconomic environment. He stated the company is well-positioned to continue helping customers succeed and create long-term value.